Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Leap Therapeutics, Inc. (LPTX) had Return on Tangible Equity of -74.06% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-15.44M |
|
-- |
|
-- |
|
$15.92M |
|
$-15.92M |
|
$0.48M |
|
$-15.44M |
|
$-15.44M |
|
$-15.44M |
|
$-15.44M |
|
$-15.44M |
|
$-15.44M |
|
$-15.92M |
|
$-15.92M |
|
41.27M |
|
41.27M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$33.87M |
|
-- |
|
$1.01M |
|
$34.88M |
|
$14.04M |
|
-- |
|
-- |
|
$14.04M |
|
$20.84M |
|
$20.84M |
|
$20.84M |
|
41.44M |
|
| Cash Flow Statement Financials | |
$-14.48M |
|
-- |
|
$-0.06M |
|
$47.25M |
|
$32.71M |
|
$-14.54M |
|
$1.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.41 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-74.06% |
|
|
Return on Tangible Equity |
-74.06% |
-44.25% |
|
-74.06% |
|
$0.50 |
|
$-0.35 |
|
$-0.35 |
|